BlossomHill Therapeutics Reports Q2 2026 Financial Results

BlossomHill Therapeutics (Nasdaq: BLSM) reported a net loss of $23.8 million, or $8.75 per share, for the second quarter of 2026, a widening from the $13.2 million loss recorded in the same period last year. The increase in losses was directly attributed to higher operational costs, with research and development expenses rising to $21.4 million from $12.5 million year-over-year, and general and administrative costs doubling to $3.3 million from $1.6 million. As of June 30, 2026, the company held $95.4 million in cash and cash equivalents, a decline from the $136.7 million reported at the end of 2025, while its accumulated deficit reached $179.8 million.

Despite the expanded quarterly losses, BlossomHill significantly strengthened its financial position through an upsized initial public offering completed in August 2026. The company raised approximately $168.3 million in gross proceeds, which it stated provides sufficient funding to sustain operations into the second quarter of 2028. This capital injection allows the clinical-stage biopharmaceutical company to continue advancing its oncology pipeline without immediate pressure for additional equity financing, as noted in the earnings release distributed via GN markets/earnings (en-US).

Lead Asset Gains Fast Track Status

The FDA granted Fast Track designation to BlossomHill’s lead candidate, BH-30643, for the treatment of advanced non-small cell lung cancer (NSCLC) with EGFR C797S-positive mutations. This regulatory milestone supports the company’s development strategy for patients who have developed resistance to prior tyrosine kinase inhibitors. The designation is intended to facilitate earlier FDA involvement and expedite the development and review of the drug, which is currently in Phase 1 clinical trials under the SOLARA study.

Updated data from the SOLARA Phase 1 trial demonstrated clinical activity in this difficult-to-treat population. In the C797S cohort, BH-30643 achieved an objective response rate of 45% and a disease control rate of 88%. These figures indicate that a substantial portion of patients experienced tumor shrinkage or stabilization, providing the primary evidence for the continued investment in this asset despite the high operational costs associated with its development.

Pipeline Expansion And Orphan Designation

Beyond its lead oncology candidate, BlossomHill is diversifying its small molecule portfolio with BH-30236, which holds FDA orphan drug designation for the treatment of acute myeloid leukemia (AML). The company also presented preclinical data for BH-501284, a pseudo-irreversible pan-KRAS inhibitor built on a novel chemical scaffold, at the AACR meeting in April. The data highlighted sustained target engagement and tumor regression at low dose levels, suggesting potential for a new class of KRAS-targeted therapies.

Operating Costs Drive Quarterly Loss

The significant year-over-year increase in R&D expenses reflects the company’s transition from early-stage discovery to active clinical trials, a phase that inherently requires substantial capital for patient enrollment and data collection. General and administrative costs also doubled, likely driven by the increased regulatory and compliance requirements associated with its recent public listing. Although these factors widened the net loss to $23.8 million, management indicated that the balance sheet remains robust enough to support these elevated spending levels through 2028.